Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | DRD5 | P21918 | 1/20 | 0.54 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11199043 | 0.98 | SLC6A2 (0.56) | SLC6A3SLC6A2CHRM1DRD3CYP1A2 | |
| SCHEMBL14814326 | 0.94 | SLC6A2 (0.51) | SLC6A3SLC6A2CHRM1DRD3CYP1A2 | |
| Hydrochloric Acid SCHEMBL9352828 | 0.92 | SLC6A2 (0.51) | SLC6A3SLC6A2CHRM1DRD3CYP1A2 | |
| SCHEMBL12064696 | 0.90 | SLC6A3 (0.53) | SLC6A3SLC6A2CHRM1DRD3CYP1A2 | |
| SCHEMBL12064697 | 0.90 | SLC6A3 (0.53) | SLC6A3SLC6A2CHRM1DRD3CYP1A2 | |
| SCHEMBL12064970 | 0.88 | HTR6 (0.46) | SLC6A3SLC6A2CHRM1DRD3CYP1A2 | |
| SCHEMBL12064968 | 0.85 | SLC6A2 (0.46) | SLC6A3SLC6A2CHRM1DRD3CYP1A2 | |
| SCHEMBL4190405 | 0.82 | DRD3 (0.55) | SLC6A3SLC6A2DRD3CYP1A2CYP2D6 | |
| SCHEMBL6616012 | 0.82 | SLC6A3 (0.44) | SLC6A3SLC6A2CHRM1DRD3CYP1A2 | |
| SCHEMBL1802062 | 0.81 | DRD3 (0.59) | SLC6A3SLC6A2CHRM1DRD3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| EP-0923575-B1 | CYCLIC ETHER COMPOUNDS AS SODIUM CHANNEL MODULATORS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-03-12 | — | — | EP | disclosed |
| US-6172085-B1 | CENTRAL NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-0923575-A1 | CYCLIC ETHER COMPOUNDS AS SODIUM CHANNEL MODULATORS | Takeda Chemical Industries, Ltd. (JP) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998008842-A1 | CYCLIC ETHER COMPOUNDS AS SODIUM CHANNEL MODULATORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-05 | — | — | WO | disclosed |
| EP-0485984-B1 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5225559-A | DIARYLMETHOXYPIPERIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0335586-B1 | PIPERIDINE & PIPERAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1993-06-02 | — | — | EP | disclosed |
| EP-0485984-A2 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES, LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| US-4929618-A | ANTIALLERGENS, ANTIHISTAMINES | UBE INDUSTRIES, LTD. (JP) | 1990-05-29 | — | — | US | disclosed |
| EP-0335586-A1 | Piperidine & piperazine derivatives, process for preparing the same and pharmaceutical compositions containing the same | UBE INDUSTRIES, LTD. (JP) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | SLC6A3 3695/4885SLC6A2 2688/4885CHRM1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.